Marginal Zone B Cell Targeting Limits Alloantigen Availability to Follicular Dendritic Cells and Mitigates Antibody-Mediated Rejection.
Chronic antibody-mediated rejection is a leading cause of allograft loss, with limited therapies that effectively target humoral immunity. Current immunosuppressive regimens primarily target T cells, leaving a critical gap in strategies to suppress antibody-driven rejection. Marginal zone (MZ) B cells are innate-like c...